SEATTLE, Wash. and VANCOUVER, British Columbia, Sept. 5, 2018 – – Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that John Bencich, Chief Financial and Operations Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference being held September 4th to 6th at The St. Regis New York.
The Company’s presentation will take place on Thursday, September 6th at 4:40pm EDT. A live webcast of the presentation can be accessed at http://ir.achievelifesciences.com/events-and-webcasts. A replay of the webcast will also be archived on Achieve’s website following the conference.
About Achieve & Cytisine
Achieve’s focus is to address the global smoking health epidemic through the development and commercialization of cytisine. Tobacco use is currently the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide1. It is estimated that 28.6% of all cancer deaths in the U.S. are attributable to cigarette smoking2.
Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Two prior, large-scale Phase 3 clinical studies of cytisine, with favorable outcomes, have been successfully completed in over 2,000 patients. The TASC trial was a 740 patient, double-blind, placebo controlled trial conceived by Professor Robert West at University College London and funded by the U.K. National Prevention Research Initiative. Th